Design Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

DSGN$10.21+5.6%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Balance Sheets

(in thousands, except share and par value data)

	June 30,	December 31,
	2025	2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$19,703	$22,563
Investment securities	196,573	222,914
Prepaid expenses and other current assets	3,518	2,563
Total current assets	219,794	248,040
Property and equipment, net	1,258	1,410
Right-of-use asset, related party	1,834	2,216
Other assets	—	427
Total assets	$222,886	$252,093
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$1,013	$2,186
Accrued expenses and other current liabilities (including related party amounts of $844 and $800 respectively)	7,734	6,276
Total current liabilities	8,747	8,462
Operating lease liability, net, related party	1,102	1,534
Total liabilities	9,849	9,996
Commitments and contingencies (See Note 8)
Stockholders’ equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized at June 30, 2025 and December 31, 2024; 56,948,126 and 56,754,341 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	6	6
Additional paid-in capital	476,738	468,830
Accumulated deficit	(264,012)	(227,214)
Accumulated other comprehensive income	305	475
Total stockholders’ equity	213,037	242,097
Total liabilities and stockholders’ equity	$222,886	$252,093

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.